Prednicarbate
Prednicarbate structure
|
Common Name | Prednicarbate | ||
|---|---|---|---|---|
| CAS Number | 73771-04-7 | Molecular Weight | 488.570 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 640.7±55.0 °C at 760 mmHg | |
| Molecular Formula | C27H36O8 | Melting Point | 110 - 112ºC | |
| MSDS | N/A | Flash Point | 209.4±25.0 °C | |
Use of PrednicarbatePrednicarbate is a topical corticosteroid agent. Prednicarbate can be used for the research of inflammatory skin diseases, such as atopic dermatitis[1][2]. |
| Name | [2-(17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl] propanoate |
|---|---|
| Synonym | More Synonyms |
| Description | Prednicarbate is a topical corticosteroid agent. Prednicarbate can be used for the research of inflammatory skin diseases, such as atopic dermatitis[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Prednicarbate (0.25%; applied daily to the ear skin area for 2 days) recovers the 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis of mice[2]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 640.7±55.0 °C at 760 mmHg |
| Melting Point | 110 - 112ºC |
| Molecular Formula | C27H36O8 |
| Molecular Weight | 488.570 |
| Flash Point | 209.4±25.0 °C |
| Exact Mass | 488.241028 |
| PSA | 116.20000 |
| LogP | 4.02 |
| Vapour Pressure | 0.0±4.3 mmHg at 25°C |
| Index of Refraction | 1.560 |
| RIDADR | NONH for all modes of transport |
|---|
|
~30%
Prednicarbate CAS#:73771-04-7 |
| Literature: Stache; Fritsch; Rupp; Hitzel; Fehlhaber Arzneimittel-Forschung/Drug Research, 1985 , vol. 35, # 12 p. 1753 - 1757 |
|
~%
Prednicarbate CAS#:73771-04-7 |
| Literature: Arzneimittel-Forschung/Drug Research, , vol. 35, # 12 p. 1753 - 1757 |
|
~%
Prednicarbate CAS#:73771-04-7 |
| Literature: Arzneimittel-Forschung/Drug Research, , vol. 35, # 12 p. 1753 - 1757 |
|
~%
Prednicarbate CAS#:73771-04-7 |
| Literature: Arzneimittel-Forschung/Drug Research, , vol. 35, # 12 p. 1753 - 1757 |
![ethyl [(8S,9S,10R,11S,13S,14S,17R)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl] carbonate structure](https://image.chemsrc.com/caspic/095/104286-02-4.png)
![[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate structure](https://image.chemsrc.com/caspic/447/5740-62-5.png)
CAS#:5740-62-5|
Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective.
J. Cancer Res. Clin. Oncol. 139(10) , 1667-72, (2013) Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9-19 % of patients... |
|
|
Drug release and skin penetration from solid lipid nanoparticles and a base cream: a systematic approach from a comparison of three glucocorticoids.
Skin Pharmacol. Physiol. 24(4) , 199-209, (2011) Solid lipid nanoparticles (SLNs) can enhance drug penetration into the skin, yet the mechanism of the improved transport is not known in full. To unravel the influence of the drug-particle interaction... |
|
|
Efficacy of crisis intervention treatment with topical corticosteroid prednicarbat with and without partial wet-wrap dressing in atopic dermatitis.
Dermatology 212(1) , 66-9, (2006) The wet-wrap treatment has been reported to be beneficial in acute episodes of atopic dermatitis (AD) skin lesions.The efficacy of topical corticosteroid prednicarbat with and without additional wet-w... |
| (11b)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)pregna-1,4-diene-3,20-dione |
| (11β)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-3,20-dioxopregna-1,4-dien-21-yl propionate |
| propanoate de 2-{(8S,9S,10R,11S,13S,14S,17R)-17-[(éthoxycarbonyl)oxy]-11-hydroxy-10,13-diméthyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodécahydro-3H-cyclopenta[a]phénanthrén-17-yl}-2-oxoéthyle |
| 11b,17,21-Trihydroxypregna-1,4-diene-3,20-dione 17-(Ethyl Carbonate) 21-Propionate |
| 2-{(8S,9S,10R,11S,13S,14S,17R)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl}-2-oxoethylpropanoat |
| Dermatop |
| 11β,17,21-Trihydroxypregna-1,4-diene-3,20-dione 17-(ethyl carbonate) 21-propionate |
| 2-{(8S,9S,10R,11S,13S,14S,17R)-17-[(ethoxycarbonyl)oxy]-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl}-2-oxoethyl propanoate |
| (11β)-17-[(ethoxycarbonyl)oxy]-11-hydroxy-3,20-dioxopregna-1,4-dien-21-yl propanoate |
| Carbonic acid, ethyl (11β)-11-hydroxy-3,20-dioxo-21-(1-oxopropoxy)pregna-1,4-dien-17-yl ester |
| Pregna-1,4-diene-3,20-dione, 17-((ethoxycarbonyl)oxy)-11-hydroxy-21-(1-oxopropoxy)-, (11β)- |
| Prednicarbate (200 mg) |
| Regemt |
| Prednicarbate |
| HOE-777 |
| S 77 0777 |
| Prednisolone 17-(ethyl carbonate) 21-propionate |
| Regenit |
| Prednitop |
| S-77-0777 |
| Prednisolone 17-Ethylcarbonate 21-Propionate |